Radiolabeled antibodies directed at CD45 for conditioning prior to allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome

Therapeutic Advances in Hematology

Volumn 3, Issue 1, 2012, Pages 5-16

  Orozco, Johnnie J ^a   Zeller, Jill ^b   Pagel, John M ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

antibodies; CD45; hematopoietic cell transplantation; radioimmunotherapy

Indexed keywords

ACTINIUM; ACTINIUM 227; ASTATINE 211; BISMUTH 213; CD45 ANTIGEN; COPPER 67; IODINE 131; LUTETIUM 177; RADIOISOTOPE; RHENIUM 188; UNCLASSIFIED DRUG; YTTRIUM 90;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; HEMATOLOGIC DISEASE; HUMAN; ISOTOPE LABELING; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; WHOLE BODY RADIATION;

EID: 84993660901     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620711422265     Document Type: Review

References (34)

1. Andres T.L. Kadin M.E. (1983) Immunological markers in the differential-diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. Am J Clin Pathol 79: 546–552.
2. Appelbaum F.R. Matthews D.C. Eary J.F. Badger C.C. Kellogg M. Press O.W. et al (1992) The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 54: 829–833.
3. Bennett J.M. Young M.L. Andersen J.W. Cassileth P.A. Tallman M.S. Paietta E. et al (1997) Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer 80(11 Suppl): 2205–2209.
4. Bethge W.A. Wilbur D.S. Storb R. Hamlin D.K. Santos E.B. Brechbiel M.W. et al (2004) Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study. Transplantation 78: 352–359.
5. Bunjes D. Buchmann I. Duncker C. Seitz U. Kotzerke J. Wiesneth M. et al (2001) Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 98: 565–572.
6. Clift R.A. Buckner C.D. Appelbaum F.R. Bearman S.I. Petersen F.B. Fisher L.D. et al (1990) Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76: 1867–1871.
7. Clift R.A. Buckner C.D. Appelbaum F.R. Bryant E. Bearman S.I. Petersen F.B. et al (1991) Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 77: 1660–1665.
8. Clift R.A. Buckner C.D. Appelbaum F.R. Sullivan K.M. Storb R. Thomas E.D. (1998) Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood 92: 1455–1456.
9. Glatting G. Mueller M. Koop B. Hohl K. Friesen C. Neumaier B. et al (2006) Anti-CD45 monoclonal anti-body YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med 47: 1335–1341.
10. Gyurkocza B. Storb R. Storer B.E. Chauncey T.R. Lange T. Shizuru J.A. et al (2010) Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 28: 2859–2867.
11. Jurcic J.G. (2005) Immunotherapy for acute myeloid leukemia. Curr Oncol Rep 7: 339–346.
12. Lin Y. Pagel J.M. Axworthy D. Pantelias A. Hedin N. Press O.W. (2006) A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res 66: 3884–3892.
13. Lowenberg B. Suciu S. Archimbaud E. Haak H. Stryckmans P. de Cataldo R. et al (1998) Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy–the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch–Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 16: 872–881.
14. Matthews D.C. Appelbaum F.R. Eary J.F. Fisher D.R. Durack L.D. Hui T.E. et al (1999) Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94: 1237–1247.
15. Matthews D.C. Appelbaum F.R. Eary J.F. Hui T.E. Fisher D.R. Martin P.J. et al (1991) Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. Blood 78: 1864–1874.
16. Mulford D.A. Jurcic J.G. (2004) Antibody-based treatment of acute myeloid leukaemia. Expert Opin Biol Therapy 4: 95–105.
17. Nakamae H. Wilbur D.S. Hamlin D.K. Thakar M.S. Santos E.B. Fisher D.R. et al (2009) Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res 69: 2408–2415.
18. Nemecek E.R. Hamlin D.K. Fisher D.R. Krohn K.A. Pagel J.M. Appelbaum F.R. et al (2005) Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model. Clin Cancer Res 11: 787–794.
19. Omary M.B. Trowbridge I.S. Battifora H.A. (1980) Human homolog of murine T 200 glycoprotein. J Exp Med 152: 842–852.
20. Pagel J.M. Appelbaum F.R. Eary J.F. Rajendran J. Fisher D.R. Gooley T. et al (2006) 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107: 2184–2191.
21. Pagel J.M. Gooley T.A. Rajendran J. Fisher D.R. Wilson W.A. Sandmaier B.M. et al (2009 a) Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 114: 5444–5453.
22. Pagel J.M. Hedin N. Drouet L. Wood B.L. Pantelias A. Lin Y. et al (2008) Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood 111: 2261–2268.
23. Pagel J.M. Matthews D.C. Kenoyer A. Hamlin D.K. Wilbur D.S. Fisher D.R. et al (2009 b) Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. Cancer Res 69: 185–192.
24. Pagel J.M. Kenoyer A.L. Back T. Hamlin D.K. Wilbur D.K. Fisher D.R. et al (2011) Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeoloid leukemia xenograft model. Blood 118: 703–711.
25. Press O. Howell-Clark J. Anderson S. Bernstein I. (1994) Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83: 1390–1397.
26. Press O.W. Eary J.F. Appelbaum F.R. Martin P.J. Badger C.C. Nelp W.B. et al (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329: 1219–1224.
27. Ringhoffer M. Blumstein N. Neumaier B. Glatting G. Harsdorf S. Buchmann I. et al (2005) Re-188 or Y-90-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I–II study. Br J Haematol 130: 604–613.
28. Rosenblat T.L. McDevitt M.R. Mulford D.A. Pandit-Taskar N. Divgi C.R. Panageas K.S. et al (2010) Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 16: 5303–5311.
29. Ruutu T. Hanninen A. Jarventie G. Koistinen P. Koivunen E. Katka K. et al (1997) Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Leuk Res 21: 133–138.
30. Sandmaier B.M. Bethge W.A. Wilbur D.S. Hamlin D.K. Santos E.B. Brechbiel M.W. et al (2002) Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 100: 318–326.
31. Scheinberg D.A. Lovett D. Divgi C.R. Graham M.C. Berman E. Pentlow K. et al (1991) A phase I trial of monoclonal antibody M 195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9: 478–490.
32. Sharkey R.M. Rossi E.A. McBride W.J. Chang C.-H. Goldenberg D.M. (2010) Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Sem Nucl Med 40: 190–203.
33. Sieber T. Schoeler D. Ringel F. Pascu M. Schriever F. (2003) Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells. Br J Haematol 121: 458–461.
34. Weiden P.L. Breitz H.B. Press O. Appelbaum J.W. Bryan J.K. Gaffigan S. et al (2000) Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I / II study results. Cancer Biother Radiopharm 15: 15–29.